On the device front, Hahn will be taking over FDA as it grapples with a number of device issues including:
Three different groups of medical devices in Class I will get an additional four years (until May 26, 2024) to come into compliance with the new regulation. These are devices (large volume and low risk) that are in full compliance with the current Medical Device Directive (MDD) and may remain or be placed on the market:
European medical device regulation timetable:
Dexcom Follow app server outage left many parents of diabetic children without their usual ability to remotely track blood sugar levels from continuous glucose monitors.
A service that enables data streaming and alerts to parents, spouses or other caregivers’ smartphones — went down the weekend following Thanksgiving and was not entirely resolved until the middle of the following week.
The ultimate concern is that a person’s blood glucose levels drop dangerously low, while sleeping or otherwise, without anyone serving as a backup for them to realize it and take corrective steps.
The FDA is aware of the issue and will be working with Dexcom to remediate it. The agency granted marketing authorization to the Dexcom cloud software in October 2014.
© 2021 BeanStock Ventures